CD7 antibodies

CD7 antibodies

Clone: CD7-6B7
CD7-6B7 recognizes the human CD7 antigen, a single-pass type I membrane protein, also known as leu-9 or GP40. CD7 appears early in T cell ontogeny and is expressed by most T cells in the periphery. It is also found on NK cells, hematopoietic progenitors, monocytes, acute lymphocytic leukemia, and some acute myeloid leukemia cells. Although the ligand is yet not identified, CD7 has been recognized as a costimulatory molecule. CD7 activates phosphatidylinositol 3-kinase which is involved in CD7-mediated regulation of integrin adhesiveness. Furthermore, it has been reported that the β-galactoside-binding lectin galectin-1 binds CD7, leading to induction of apoptosis of thymocytes and T cells, with implications for certain autoimmune diseases and T cell lymphomas.

Applications

Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis.
Expression of CD7 may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Technical specifications

  • Antigen: CD7
  • Clone: CD7-6B7
  • Isotype: mouse IgG2aκ
  • Molecular mass of antigen [kDa]: 23
  • Distribution of antigen: T cells, NK cells, monocytes, other
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates: APC
  • Selected references

    1. Gallacher, L. et al. (2000)
      Isolation and characterization of human CD34
      Lin
      and CD34
      +
      Lin
      hematopoietic stem cells using cell surface markers AC133 and CD7.
      Blood 95(ARVO Annual Meeting Abstract): 2813-2820
    2. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
    3. Knapp, W. et al. (eds) Leukocyte Typing IV Oxford, Oxford University Press
    4. Kobayashi, S. et al. (2013) The CD3 versus CD7 plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-I. PLoS One 8(1): e53728
    5. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
    6. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
    7. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
    8. Wood BL et al. (2007) 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin. Cytom. 72: 14-22
    9. Aruffo, A. et al. (1987) Molecular cloning of two CD7 (T-cell leukemia antigen) cDNAs by a COS cell expression system. EMBO J. 6(11): 3313-3316
    10. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
  • Brochures and posters

  • Certificates

    Please follow this
    link
    to download the Certificate of Conformity (CoC) by lot number.
Product options: 1
170-078-050

CD7-APC

for 100
tests
-